During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|May 3, 2019
Case Review: Progression in Follicular Lymphoma
Case Review: Progression in Follicular Lymphoma
Advertisement
Case:A 70-Year-Old Man With Follicular Lymphoma
H & P:
- A 70-year-old man presents with night sweats and general fatigue
- PMH: hypertension, no history of MACE
- PE: Groin is tender to touch, no tenderness in abdomen
- Initially diagnosed with bilateral axillary contiguous stage II FL 5.5 years ago
- Grade 2 FL, 4 masses (each >3 cm)
- FLIPI status: high risk
Current biopsy and labs:
- Biopsy: grade 2 FL without transformation
- ECOG performance status: 1
- Hematologic results
- ANL: 1200 /µL
- Platelets: 105,000 /µL
- Hemoglobin: 11.9 g/dL
- LDH: 335 U/L
- eGFR: 75 mL/min/1.732
- Imaging: PET/CT reveals inguinal lymphadenopathy, with largest mass 8.5 cm
Treatment and disease history
- Front-line BR
- Completed 6 cycles, achieved PR by 3 months
- Maintained PR for 20 months before developing fever and mediastinal lymphadenopahty
- Second-line R-CHOP
- Competed 6 cycles, achieved PR at 3 months
- PR maintained for 5 months
- Time since completion of last treatment: 5 months
Current treatment
- Started on single-agent idelalisib 150 mg twice a day
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5